George Shahin, MD
Hematology & Oncology · Biloxi, MSNPI 1508278912
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,036 of the $2,331 with a category attached, or 87.3%. It is spread thinly across 30 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $764 and has fallen 88.8% since, to $86 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MS, where the typical reported total is $9,632.
Across 77 payments — averaging $30.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$284
- Exelixis Inc.$254
- Regeneron Healthcare Solutions, Inc.$199
- Merck$176
- AbbVie$165
- EMD Serono, Inc.$154
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,03687%
- Education$29613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 3 | $284 |
| Exelixis Inc. | 2 | $254 |
| Regeneron Healthcare Solutions, Inc. | 5 | $199 |
| Merck | 6 | $176 |
| AbbVie | 6 | $165 |
| EMD Serono, Inc. | 3 | $154 |
| E.r. Squibb & Sons, L.L.C. | 3 | $127 |
| AstraZeneca | 7 | $103 |
| Seagen Inc. | 1 | $103 |
| Bristol Myers Squibb | 4 | $81 |
| Ipsen Biopharmaceuticals, Inc | 4 | $61 |
| Incyte Corporation | 3 | $60 |
| Sanofi | 3 | $54 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $50 |
| Gilead | 2 | $44 |
| Eagle Pharmaceuticals, Inc. | 2 | $43 |
| ADC Therapeutics America, Inc. | 2 | $41 |
| GSK | 2 | $36 |
| Stemline Therapeutics Inc. | 2 | $32 |
| Beigene USA, Inc. | 2 | $30 |
| Puma Biotechnology, Inc. | 2 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Sobi, Inc | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,331 in reported general payments places this provider in the 15th percentile of 57 hematology & oncology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 12 | $224 |
| Duloxetine Hcl | 13 | $168 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Biloxi
- Charles JacocksBiloxi$797
- Solly ChedidPascagoula$1.7M
- Carter MilnerJackson$248K
- Guangzhi QuJackson$59K
- Jennifer EubanksMeridian$44K
- Daniel PattersonPascagoula$36K
- John HeneganJackson$35K
- Pamela TuliGulfport$27K
- Sonia BennSouthaven$26K
- Ronald DelrieMcComb$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.